| ALT | alanine transaminase |
| APC | antigen-presenting cells |
| AST | aspartate transaminase |
| COVID-19 | coronavirus disease 2019 |
| CRRT | continuous renal replacement therapy |
| CRP | c-reactive protein |
| CTLA-4 | T-lymphocyte-associated protein 4 |
| ECOG | Eastern Cooperative Oncology Group performance status |
| eGFR | estimated glomerular filtration rate |
| GIST | gastrointestinal stromal tumors |
| ICIs | immune checkpoint inhibitors |
| ICU | intensive care unit |
| IMT | immunotherapy |
| irAE | immune-related adverse event |
| LDH | lactose dehydrogenase |
| MHC | major histocompatibility complex |
| NA | not performed |
| NSCLC | non-small-cell lung cancer |
| NK | natural killer cells |
| OS | overall survival |
| PD-1 | programmed cell death-1 |
| PD-L1 | programmed cell death Ligand 1 |
| RCC | renal cell carcinoma |
| SARS-CoV-2 | severe acute respiratory syndrome coronavirus 2 |
| TCR | T-cell receptor |
| WBC | white blood cell |